Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors

19 Dec 2024

Abstract excerpt

Understanding the genomic landscape of breast cancer brain metastases (BCBMs) is key to developing targeted treatments. In this study, targetable genomic profiling was performed on 822 BCBMs, 11,988 local breast cancer (BC) biopsies and 15,516 non-central nervous system (N-CNS) metastases (all unpaired samples) collected during the course of routine clinical care by Foundation Medicine Inc (Boston, MA)....

Topics

Join the communities discussing this publication.

Brain Metastases and Treatment
Lung Cancer Research Studies
Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39706915
DOI: 10.1038/s41698-024-00761-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitorsPMID 39706915Read ↗

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.Semantic proximity Read ↗

Genomic and immune profiling of breast cancer brain metastasesSemantic proximity Read ↗

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain MetastasesSemantic proximity Read ↗

Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive DiseaseSemantic proximity Read ↗

Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.Semantic proximity Read ↗

Comprehensive molecular biomarker identification in breast cancer brain metastases.Semantic proximity Read ↗

Genomics of breast cancer brain metastases: a meta-analysis and therapeutic implicationsSemantic proximity Read ↗

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.Semantic proximity Read ↗

The genomic landscape of breast cancer brain metastases: a systematic review.Semantic proximity Read ↗

Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.